The importance of these processes in organismal health is highlighted by the fact that mutations in MFN2 or OPA1 lead to Charcot-Marie-Tooth syndrome Type 2A (CMT2A) and dominant optic atrophy (DOA), respectively (Alexander et al, 2000; Delettre et al, 2000; Züchner et al, 2004; Stuppia et al, 2015). This evidence concerns the gene OPA1 and autosomal dominant optic atrophy.